Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

75%

9 trials in Phase 3/4

Results Transparency

13%

1 of 8 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
9(75.0%)
Phase 2
2(16.7%)
Phase 1
1(8.3%)
12Total
Phase 3(9)
Phase 2(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT07102511Phase 3Enrolling By Invitation

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

Role: lead

NCT05004675Phase 3Completed

Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

Role: lead

NCT04798430Phase 3Enrolling By Invitation

Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction

Role: lead

NCT04797104Phase 3Completed

Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction

Role: lead

NCT04806893Phase 3Unknown

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Role: lead

NCT04797247Phase 3Unknown

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

Role: lead

NCT04790513Phase 3Completed

Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients

Role: lead

NCT04034485Phase 3Completed

Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH

Role: lead

NCT05234775Phase 3Completed

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

Role: lead

NCT03847974Phase 2Completed

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

Role: lead

NCT03549260Phase 2Completed

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

Role: lead

NCT03545438Phase 1Completed

Study to Evaluate the Safety, PK, and Pharmacodynamics of LIB003

Role: lead

All 12 trials loaded